MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • VistaGen Therapeutics, Inc. (VSTA) Management Guides Company Advancement With Broad Range Of Industry Expertise 0 comments
    Nov 8, 2013 5:38 PM | about stocks: VTGN

    VistaGen Therapeutics has developed a versatile human pluripotent stem cell (hPSC) technology platform based on the controlled differentiation of hPSCs into mature, non-transformed, human cells. The company's goal is to integrate this hPSC technology with modern medicinal chemistry to create a diverse drug pipeline consisting of new, proprietary, small molecule variants (Drug Rescue Variants) of once-promising drug candidates.

    At the forefront of operations is CEO Shawn K. Singh, J.D., who has more than 20 years of experience working with successful public and private biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO).

    H. Ralph Snodgrass, Ph.D., founder and former CEO of VistaGen, is the company's chief scientific officer. He has more than 18 years of experience in senior biotechnology management and, among other achievements, is a published and recognized pioneering expert in stem cell biology with more than 20 years of experience using stem cells as biological tools for drug discovery and development.

    Jerrold D. Dotson provides financial direction for VistaGen as the company's chief financial officer. His background covers a broad base of financial experience, including holding various positions in the finance and administration department of Calypte Biomedical Corp., including his last position as vice president of finance and administration and corporate secretary, California & Hawaiian Sugar Company, and The Clorox Company.

    Vice president of corporate development, A. Franklin Rice, MBA, joined VistaGen in 1999. He has been employed in the biotechnology industry since 1988, previously serving as senior director of business development at Genencor International and vice president of biotechnology and pharmaceuticals for Bechtel Group where he was responsible for global sales and marketing of consulting services to biotechnology and pharmaceutical companies.

    Collectively, VistaGen's management team is advancing the company's Human Clinical Trials in a Test Tube™ and working to strengthen the company's presence in the lucrative biotech industry.

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: VTGN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.